Female Fertility in Your 20s vs 30s vs 40s

Less abruptly than the usual framing suggests, and more steadily. In the best-designed study of natural conception — 782 couples across seven European natural-family-planning centres, with daily intercourse records so that timing could be adjusted for — the estimated share of couples who had not conceived within 12 cycles was 8% for women aged 19-26, 13-14% for women aged 27-34, and 18% for women aged 35-39.

Two findings from that same study get left out of most age articles, and both matter more than the headline. Complete sterility in that cohort of 782 couples was estimated at about 1% and did not change with age. And of the couples in that cohort who had not conceived within 12 cycles, between 43% and 63% went on to conceive in the following 12 cycles, depending on age. The authors' own conclusion: increased infertility in older couples comes from lower monthly fertility rates rather than from absolute sterility.

What that means in plain terms: age makes each month less likely, not the outcome impossible. Roughly one in five couples in their late thirties will not be pregnant after a year of trying — and about half of those will be pregnant after the second year.

No. The joint ACOG and ASRM committee opinion on age-related fertility decline puts it differently: fecundity decreases gradually but significantly from approximately age 32, and decreases more rapidly after age 37. Two numbers, neither of them 35, and a slope rather than an edge.

35 survives as a milestone because it is where the advice changes, not where the biology does. The same opinion says women older than 35 should have an expedited evaluation and be treated after 6 months of trying rather than the usual 12, and that women older than 40 warrant more immediate evaluation and treatment. That is a rule about how long to wait before asking for help.

The day-to-day mechanism is unglamorous. In the same cohort of 782 couples, measured against the day of ovulation, nearly all pregnancies occurred inside a six-day fertile window, and that window was not shorter in older women. What fell was the chance on each of those days — roughly twice as high for women aged 19-26 as for women aged 35-39.

This is where the internet's numbers are worst, so here is the whole curve from one source: 421,201 pregnancies in Norway between 2009 and 2013, with miscarriages captured from national registers.

• Under 20: 15.8% of pregnancies
• 20-24: 11.3%
• 25-29: 9.8% — the lowest, with the absolute minimum of 9.5% at age 27
• 30-34: 10.8%
• 35-39: 16.7%
• 40-44: 32.2%
• 45 and over: 53.6%
• All ages: 12.8%

Note the correction, because this page previously carried the wrong figure: the commonly quoted “about half” applies to age 45 and over. At 40-44 it is about a third of pregnancies. The curve is also J-shaped rather than a straight line — risk is higher in the youngest mothers than at 25-29, and the authors call that finding curious and unexplained.

Separately, and independently of age, miscarriage recurs: the age-adjusted odds ratio was 1.54 after one miscarriage, 2.21 after two and 3.97 after three consecutive ones.

The dominant reason is chromosomal. The largest single series looked at 15,169 consecutive blastocyst biopsies screened for whole-chromosome errors. Aneuploidy rose predictably after age 26, and the useful figure for anyone weighing IVF is the chance of a cycle producing no normal embryo at all: 2% to 6% for women aged 26 to 37, 33% at age 42, and 53% at age 44. Overall risk did not measurably change after 43.

Two things in that dataset cut against the standard scare. Aneuploidy was above 40% in women aged 23 and under, so a young egg is not automatically a normal egg; and the lowest risk sat between ages 26 and 30, not in the early twenties.

The denominator matters here. These are blastocysts from women already having IVF, biopsied because they reached the blastocyst stage. That is not the same population as women conceiving naturally, and the percentages should not be read across to them.

This is the mistake that does the most damage in this topic. A quoted “40% success rate” means nothing until you know whose eggs and what the denominator was — per cycle started, per transfer, pregnancy or live birth. Three separate ladders:

• Natural conception. Falls steadily from the late twenties. Per the 782-couple cohort above: 8% not pregnant at 12 cycles at 19-26, rising to 18% at 35-39.
• IVF with your own eggs. Falls steeply, because it depends on the same eggs. In validated UK HFEA data for 2019, live birth per embryo transferred was 32% for patients under 35, 25% at 35-37, 19% at 38-39, and at or below 5% from age 43 — a level HFEA notes has been consistent for patients 43 and over across three decades.
• IVF with donor eggs. Barely falls with the recipient's age at all. HFEA reports that using donor eggs raises the chance of a live birth to above 30% for all age groups. Only 17% of patients aged 40 and over used donor eggs in 2019.

That third line is the whole reason the distinction matters. When a clinic quotes a live birth rate for a 44-year-old, the number is almost entirely determined by which of these three it refers to. Ask.

Separately: none of this is a recommendation. If you are weighing freezing eggs now against treating later, the egg freezing guide and best age to conceive deal with that decision directly.

No, and this is the single most over-sold test in fertility. AMH measures how many eggs are likely to respond to stimulation. It does not measure whether you can get pregnant this year.

The direct test of that: 981 women aged 30 to 44 with no history of infertility, who had been trying for three months or less, were recruited from the community and followed to pregnancy. Among the 750 who gave samples, women with low AMH (below 0.7 ng/mL, n = 84) had a predicted probability of conceiving within 12 cycles of 84% (95% CI 70-91), against 75% (95% CI 70-79) for the 579 women with normal values. Not significantly different. High FSH behaved the same way. The authors' conclusion is explicit: these findings do not support using AMH or FSH to assess natural fertility in women like these.

Where AMH genuinely earns its place is IVF planning. An individual patient data meta-analysis pooling 28 databases and 5,705 women undergoing IVF found AMH predicted poor ovarian response well on its own — area under the curve 0.78, against 0.61 for age alone. For predicting an ongoing pregnancy, age was the best single predictor at 0.57, and none of the ovarian reserve tests added anything to it.

So: a low AMH in your thirties is a reason to expect fewer eggs from a stimulation cycle. It is not a countdown, and on this evidence it is not a reason to rush a decision about your own body.

Structured by the decision rather than the decade, because the decade only changes the timing:

1. Under 35 and trying: 12 months of trying before an evaluation is the standard threshold. Track the six-day fertile window rather than a supplement regimen.
2. 35 to 39 and trying: 6 months, per ACOG and ASRM, and both partners assessed at the same time — not the woman first.
3. 40 and over and trying: immediate evaluation and treatment, per the same opinion. At this point the most consequential question is whose eggs, because that is what moves the number most.
4. Not trying yet: egg freezing is a decision about future options, not about present fertility, and it should be priced as one.
5. Whatever the stage: know what a cycle costs before you start. In an ICMR study of 148 couples (n = 148) at five Indian tertiary hospitals, mean out-of-pocket expenditure per IVF cycle was ₹1,10,104 in public hospitals versus ₹2,30,668 in private ones. Of that total, drug costs were 55%; of the 148 couples, only 5% had insurance cover, and about 30% of 148 couples met the definition of catastrophic health expenditure.

Sometimes the answer is testing, timing or a simpler treatment rather than IVF. An evaluation is how you find out which.

Everything above has an edge, and the edges are where this genre usually starts inventing:

• No age at which conception becomes impossible. Dunson estimated sterility at about 1% and unchanging with age, and that cohort enrolled women only to age 40. Nothing here supports a statement about any individual's chance being zero.
• The aneuploidy curve is an IVF population. Those 15,169 blastocysts came from women in treatment. They describe embryos that reached biopsy, not eggs in the general population.
• HFEA's more recent years are not validated. HFEA states that outcome data from 2019 to 2022 has not yet been validated, which is why the figures here are the 2019 published set and why the 40-42 band is not quoted.
• No Indian age-stratified ART outcome data is cited. The IVF percentages are UK. No comparable published, age-banded Indian series was located for this page. The cost figures are Indian; the outcome figures are not.
• Miscarriage figures are Norwegian registry data. Register-captured miscarriage misses very early losses, so the true rate at every age is higher than 12.8% overall — the shape of the curve is the transferable part, not the absolute level.
• Nothing here says a supplement changes egg quality with age. This page makes no claim either way, because no primary evidence was retrieved for one.